Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

20.36 +1.09 (+5.66%)

Delayed Quote Updated: 10:41 AM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

4 Analysts Have This to Say About Legend Biotech ↗

December 20, 2022

Via Benzinga

Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims ↗

December 08, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022 ↗

December 06, 2022

Via Benzinga

Short Volatility Alert: Legend Biotech Corporation ↗

June 24, 2022

On Thursday, shares of Legend Biotech Corporation (NASDAQ: LEGN) experienced volatile short activity. After the activity, the stock price went up +6.97% to $51.10. The...

Via Benzinga

Legend Biotech Shares Move Higher After Bullish BMO Pitch ↗

June 17, 2022

Via Benzinga

Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

November 21, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Announces Participation in Upcoming Investor Conferences

November 04, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022

November 03, 2022

From Legend Biotech Corporation

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗

November 02, 2022

Upgrades

Via Benzinga

Carnival, Amazon, Iamgold And Other Big Gainers From Tuesday ↗

October 19, 2022

U.S. stocks closed higher on Monday, with the Dow Jones gaining more than 300 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Why Legend Biotech's Shares Jumped 14.2% On Tuesday ↗

October 18, 2022

The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors

September 29, 2022

Via AB Newswire

Why Quoin Pharmaceuticals Shares Jumped By More Than 44%; Here Are 57 Biggest Movers From Yesterday ↗

October 19, 2022

Gainers COMSovereign Holding Corp. (NASDAQ: COMS) shares jumped 170.1% to close at $0.1194 on Tuesday after gaining 4% on Monday.

Via Benzinga

CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

September 27, 2022

From Legend Biotech Corporation

Via Business Wire

Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022

September 15, 2022

From Legend Biotech Legend Biotech Corporation

Via Business Wire

No Early Relief for JW Therapeutics from Cancer Wonder Drug ↗

September 07, 2022

Key Takeaways: JW Therapeutics prices its new cancer therapy at around a million yuan, with the high production costs hard to bring down. Large-scale market expansion is not going to be easy The...

Via Benzinga

Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗

September 01, 2022

On Thursday, Legend Biotech stock had its Relative Strength (RS) Rating upgraded to 91, up from 87 a day earlier.

Via Investor's Business Daily

Legend Biotech Announces Participation in Upcoming Investor Conferences

August 19, 2022

From Legend Biotech

Via Business Wire

NexImmune Pauses Developing Multiple Myeloma Hopeful, Citing Competition ↗

August 16, 2022

NexImmune Inc (NASDAQ: NEXI) cited the competitive environment in the blood cancer space as the reason for

Via Benzinga

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022

August 05, 2022

From Legend Biotech Corporation

Via Business Wire

Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board

August 04, 2022

From Legend Biotech

Via Business Wire

Week In Review: China Biopharma Tops $2.8 Billion In Week's Dealmaking ↗

July 30, 2022

CSPC Pharma out-licensed global rights for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. CSPC will receive a $27 million upfront payment and up to $148...

Via Talk Markets

PayPal, Alphabet And Some Other Big Stocks Recording Gains On Wednesday ↗

July 28, 2022

U.S. stocks closed sharply higher on Wednesday, with the Dow Jones jumping more than 400 points. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy ↗

July 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Walmart, Shopify And Some Other Big Stocks Recording Losses On Tuesday ↗

July 27, 2022

U.S. stocks closed lower on Monday, with the Nasdaq Composite dropping more than 200 points. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Legend Biotech Corporation Announces Pricing of Public Offering

July 26, 2022

From Legend Biotech Corporation

Via Business Wire

Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate ↗

July 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 25, 2022

Gainers

Via Benzinga

Legend Biotech Corporation Announces Proposed Public Offering

July 25, 2022

From Legend Biotech Corporation

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.